HC Wainwright Has Bearish Forecast for HOWL Q1 Earnings

Werewolf Therapeutics, Inc. (NASDAQ:HOWL) – Equities research analysts at HC Wainwright lowered their Q1 2025 EPS estimates for Werewolf Therapeutics in a report released on Wednesday, March 12th. HC Wainwright analyst A. Maldonado now anticipates that the company will earn ($0.43) per share for the quarter, down from their previous forecast of ($0.38). HC Wainwright has a “Buy” rating and a $15.00 price objective on the stock. The consensus estimate for Werewolf Therapeutics’ current full-year earnings is ($1.56) per share. HC Wainwright also issued estimates for Werewolf Therapeutics’ Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.47) EPS, Q4 2025 earnings at ($0.30) EPS, FY2025 earnings at ($1.65) EPS, FY2026 earnings at ($0.81) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($1.07) EPS and FY2029 earnings at ($0.64) EPS.

Werewolf Therapeutics (NASDAQ:HOWL) last announced its quarterly earnings results on Tuesday, March 11th. The company reported ($0.46) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.03). Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 58.83%.

HOWL has been the subject of several other reports. JMP Securities decreased their price objective on Werewolf Therapeutics from $12.00 to $4.00 and set a “market outperform” rating for the company in a report on Tuesday, January 14th. Wedbush reissued an “outperform” rating and issued a $8.00 price objective on shares of Werewolf Therapeutics in a report on Wednesday, March 12th.

Werewolf Therapeutics Stock Performance

Shares of Werewolf Therapeutics stock opened at $1.17 on Monday. The firm has a market capitalization of $52.45 million, a P/E ratio of -0.76 and a beta of 0.37. Werewolf Therapeutics has a 52 week low of $1.03 and a 52 week high of $6.89. The firm’s 50 day moving average is $1.34 and its two-hundred day moving average is $1.79. The company has a quick ratio of 10.10, a current ratio of 10.10 and a debt-to-equity ratio of 0.29.

Institutional Investors Weigh In On Werewolf Therapeutics

Hedge funds have recently modified their holdings of the stock. Walleye Capital LLC lifted its holdings in Werewolf Therapeutics by 10.7% in the third quarter. Walleye Capital LLC now owns 108,968 shares of the company’s stock valued at $231,000 after acquiring an additional 10,528 shares during the period. PFM Health Sciences LP lifted its holdings in Werewolf Therapeutics by 4.9% in the third quarter. PFM Health Sciences LP now owns 3,398,747 shares of the company’s stock valued at $7,205,000 after acquiring an additional 157,673 shares during the period. State Street Corp lifted its holdings in Werewolf Therapeutics by 12.4% in the third quarter. State Street Corp now owns 476,439 shares of the company’s stock valued at $1,010,000 after acquiring an additional 52,528 shares during the period. XTX Topco Ltd acquired a new stake in Werewolf Therapeutics in the third quarter valued at $45,000. Finally, Barclays PLC lifted its holdings in Werewolf Therapeutics by 130.1% in the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock valued at $116,000 after acquiring an additional 30,990 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.